Last $7.54 USD
Change Today +0.03 / 0.40%
Volume 4.6K
RXDX On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

ignyta inc (RXDX) Snapshot

Open
$7.51
Previous Close
$7.51
Day High
$7.56
Day Low
$7.50
52 Week High
01/29/14 - $20.00
52 Week Low
12/20/13 - $1.00
Market Cap
147.6M
Average Volume 10 Days
19.5K
EPS TTM
--
Shares Outstanding
19.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IGNYTA INC (RXDX)

Related News

No related news articles were found.

ignyta inc (RXDX) Related Businessweek News

No Related Businessweek News Found

ignyta inc (RXDX) Details

Ignyta, Inc., a precision medicine biotechnology company, is engaged in discovering or acquiring, developing, and commercializing new drugs for cancer patients. Its products pipeline consists of RXDX-101, a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors, ROS1, and ALK proteins, which is in a Phase I/II clinical study in molecularly defined patient populations for the treatment of solid tumors; and RXDX-102, a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors. The company was founded in 2011 and is based in San Diego, California.

33 Employees
Last Reported Date: 08/13/14
Founded in 2011

ignyta inc (RXDX) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $437.5K
Chief Operating Officer
Total Annual Compensation: $305.0K
Compensation as of Fiscal Year 2013.

ignyta inc (RXDX) Key Developments

Ignyta, Inc. Appoints Adrian Senderowicz as Chief Medical Officer and Senior Vice President, Clinical Development and Regulatory Affairs; Announces Unaudited Earnings Results for the Second Quarter Ended June 30, 2014

On August 11, 2014, Ignyta, Inc. appointed Adrian Senderowicz, M.D., as company’s Chief Medical Officer and Senior Vice President, Clinical Development and Regulatory Affairs, effective immediately. Prior to joining Ignyta, Senderowicz was Vice President, Global Regulatory Oncology at Sanofi, a position he held from September 2013 to August 2014. Prior to Sanofi, Senderowicz was Chief Medical Officer at Tokai Pharmaceuticals from July 2012 to March 2013. From July 2008 to March 2012, Senderowicz held positions of increasing responsibility, including Senior Medical Director, Oncology Clinical Development, at AstraZeneca. The company announced unaudited earnings results for the second quarter ended June 30, 2014. For the quarter, the company reported loss from operations of USD 5,465,000 compared to USD 1,112,000 a year ago. Loss before income tax was USD 5,423,000 compared to USD 1,141,000 a year ago. Net loss was USD 5,423,000 or USD 0.28 per basic and diluted share compared to USD 1,141,000 or USD 0.84 per basic and diluted share a year ago. Revenue was USD 150,000. The company did not record any revenue for the three months ended June 30, 2013. The increase was due to a one-time service fee for research services conducted in the second quarter of 2014.

Ignyta, Inc., Q2 2014 Earnings Call, Aug 12, 2014

Ignyta, Inc., Q2 2014 Earnings Call, Aug 12, 2014

Ignyta, Inc. to Report Q2, 2014 Results on Aug 12, 2014

Ignyta, Inc. announced that they will report Q2, 2014 results After-Market on Aug 12, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RXDX:US $7.54 USD +0.03

RXDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RXDX.
View Industry Companies
 

Industry Analysis

RXDX

Industry Average

Valuation RXDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 984.2x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 420.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IGNYTA INC, please visit www.ignyta.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.